ICON Public (NASDAQ:ICLR) Releases FY24 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $14.65-$15.15 for the period, compared to the consensus estimate of $14.94. The company issued revenue guidance of $8.48-$8.72 billion, compared to the consensus revenue estimate of $8.64 billion.

ICON Public Stock Up 2.7 %

ICLR stock traded up $8.23 during mid-day trading on Friday, reaching $308.31. The company had a trading volume of 715,419 shares, compared to its average volume of 520,157. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.21 and a quick ratio of 1.21. The stock has a 50 day simple moving average of $318.89 and a two-hundred day simple moving average of $282.81. The company has a market capitalization of $25.44 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 1.42 and a beta of 1.15. ICON Public has a 52 week low of $181.92 and a 52 week high of $344.77.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. The firm had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. As a group, equities analysts predict that ICON Public will post 14.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ICLR shares. Robert W. Baird lifted their target price on ICON Public from $362.00 to $363.00 and gave the stock an outperform rating in a research note on Friday. TD Cowen lifted their target price on ICON Public from $343.00 to $349.00 and gave the stock a buy rating in a research note on Friday. Mizuho reissued a buy rating and set a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. Truist Financial lifted their price target on ICON Public from $357.00 to $367.00 and gave the stock a buy rating in a report on Friday, February 23rd. Finally, Evercore ISI decreased their price target on ICON Public from $350.00 to $330.00 and set an outperform rating on the stock in a research note on Friday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $321.64.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.